Anti-fibrillogenic and fibril-destabilizing activities of anti-Parkinsonian agents for α-synuclein fibrils in vitro

Journal of Neuroscience Research

Volumn 85, Issue 7, 2007, Pages 1547-1557

  Ono, Kenjiro ^a   Hirohata, Mie ^a   Yamada, Masahito ^a  

^a KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

Author keywords

synuclein fibrils; Anti Parkinsonian agents; Atomic force microscopy; Electron microscopy; Lewy body diseases

Indexed keywords

ALPHA SYNUCLEIN; AMYLOID PRECURSOR PROTEIN; ANTIPARKINSON AGENT; BROMOCRIPTINE; DOPAMINE; MYRICETIN; NORDIHYDROGUAIARETIC ACID; PERGOLIDE; RIFAMPICIN; SELEGILINE; THIOFLAVINE; TRIHEXYPHENIDYL;

ARTICLE; DOSE RESPONSE; DRUG MECHANISM; DRUG STRUCTURE; IN VITRO STUDY; PARKINSON DISEASE; PRIORITY JOURNAL;

ALPHA-SYNUCLEIN; ANTIPARKINSON AGENTS; BROMOCRIPTINE; DOPAMINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MOLECULAR STRUCTURE; NEUROFIBRILLARY TANGLES; PERGOLIDE; POLYMERS; SELEGILINE; TRIHEXYPHENIDYL;

EID: 34248136388     PISSN: 03604012     EISSN: 10974547     Source Type: Journal    
DOI: 10.1002/jnr.21271     Document Type: Article

References (51)

1. Asanuma M, Miyazaki I, Ogawa N. 2003. Dopamine- or L-dopa- induced neurotoxicity: the role of dopamine quinone formation and tyrosinase in a model of Parkinson's disease. Neurotox Res 5:165-176.
2. Butterfield DA, Kanski J. 2001. Brain protein oxidation in age-related neurodegenerative disorders that are associated with aggregated proteins. Mech Ageing Dev 15:945-962.
3. Chartier-Harlin MC, Kachergus J, Roumier C, Mouroux V, Douay X, Lincoln S, Levecque C, Larvor L, Andrieux J, Hulihan M, Waucquier N, Defebvre L, Amouyel P, Farrer M, Destee A. 2004. Alpha-synuclein locus duplication as a cause of familial Parkinson's disease. Lancet 364: 1167-1169.
4. Conway KA, Rochet JC, Bieganski RM, Lansbury PT Jr. 2001. Kinetic stabilization of the α-synuclein protofibril by a dopamine-α- synuclein adduct. Science 294:1346-1349.
5. Eliezer D, Kutluay E, Bussell R Jr, Browne G. 2001. Conformational properties of alpha-synuclein in its free and lipid-associated states. J Mol Biol 307:1061-1073.
6. Feany MB, Bender WW. 2000. A Drosophila model of Parkinson's disease. Nature 404:394-398.
7. Giasson BI, Duda JE, Quinn SM, Zhang B, Trojanowski JQ, Lee VM. 2002a. Neuronal alpha-synucleinopathy with severe movement disorder in mice expressing A53T human alpha-synuclein. Neuron 34:521-533.
8. Giasson BI, Ischiropoulos H, Lee VM, Trojanowski JQ. 2002b. The relationship between oxidative/nitrative stress and pathological inclusions in Alzheimer's and Parkinson's diseases. Free Radic Biol Med 32:1264-1275.
9. Goedert M. 2001. α-Synuclein and neurodegenerative diseases. Nat Rev Neurosci 2:492-501.
10. Gómez-Vargas M, Nishibayashi-Asanuma S, Asanuma M, Kondo Y, Iwata E, Ogawa N. 1998. Pergolide scavenges both hydroxyl and nitric oxide free radicals in vitro and inhibits lipid peroxidation in different regions of the rat brain. Brain Res 790:202-208.
11. Graham DG. 1978. Oxidative pathways for catecholamines in the genesis of neuromelanin and cytotoxic quinones. Mol Pharmacol 14:633-643.
12. Ibanez P, Bonnet AM, Debarges B, Lohmann E, Tison F, Pollak P, Agid Y, Durr A, Brice A. 2004. Causal relation between alpha-synuclein gene duplication and familial Parkinson's disease. Lancet 364:1169-1171.
13. Irizarry MC, Kim TW, McNamara M, Tanzi RE, George JM, Clayton DF, Hyman BT. 1996. Characterization of the precursor protein of the non-A beta component of senile plaques (NACP) in the human central nervous system. J Neuropathol Exp Neurol 55:889-895.
14. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, Saitoh T. 1995. The precursor protein of non-A beta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron 14:467-475.
15. Jarrett JT, Lansbury PT Jr. 1993. Seeding "one-dimensional crystallization" of amyloid: a pathogenic mechanism in Alzheimer's disease and scrapie? Cell 73:1055-1058.
16. Kakimura J, Kitamura Y, Takata K, Kohno Y, Nomura Y, Taniguchi T. 2001. Release and aggregation of cytochrome c and alpha-synuclein are inhibited by the antiparkinsonian drugs, talipexole and pramipexole. Eur J Pharmacol 417:59-67.
17. Kruger R, Kuhn W, Muller T, Woitalla D, Graeber M, Kosel S, Przuntek H, Epplen JT, Schols L, Riess O. 1998. Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet 18: 106-108.
18. Lange KW, Rausch WD, Gsell W, Naumann M, Oestreicher E, Riederer P. 1994. Neuroprotection by dopamine agonists. J Neural Transm Suppl 43:183-201.
19. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, Lansbury PT Jr. 2002. Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol 322:1089-1102.
20. Lee MK, Stirling W, Xu Y, Xu X, Qui D, Mandir AS, Dawson TM, Copeland NG, Jenkins NA, Price DL. 2002. Human alpha-synuclein-harboring familial Parkinson's disease-linked Ala-53→Thr mutation causes neurodegenerative disease with alpha-synuclein aggregation in transgenic mice. Proc Natl Acad Sci USA 99:8968-8973.
21. Li J, Zhu M, Rajamani S, Uversky VN, Fink AL. 2004a. Rifampicin inhibits alpha-synuclein fibrillation and disaggregates fibrils. Chem Biol 11:1513-1521.
22. Li J, Zhu M, Manning-Bog AB, Di Monte DA, Fink AL. 2004b. Dopamine and l-dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J 18:962-964.
23. Lomakin A, Teplow DB, Kirschner DA, Benedek GB. 1997. Kinetic theory of fibrillogenesis of amyloid beta-protein. Proc Nad Acad Sci USA 94:7942-7947.
24. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. 2000. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287:1265-1269.
25. Nakai S, Yoneda F. 2000. A theoretical investigation of (-)-deprenyl (selegiline) as a radical scavenger. Theor Chem Acc 104:398-406.
26. Naiki H, Gejyo F, Nakakuki K. 1997. Concentration-dependent inhibitory effects of apolipoprotein E on Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 36:6243-6250.
27. Naiki H, Hasegawa K, Yamaguchi I, Nakamura H, Gejyo F, Nakakuki K. 1998. Apolipoprotein E and antioxidants have different mechanisms of inhibiting Alzheimer's beta-amyloid fibril formation in vitro. Biochemistry 37:17882-17889.
28. Ogawa N, Tanaka K, Asanuma M, Kawai M, Masumizu T, Kohno M, Mori A. 1994. Bromocriptine protects mice against 6-hydroxydopamine and scavenges hydroxyl free radicals in vitro. Brain Res 657:207-213.
29. Ono K, Hasegawa K, Yoshiike Y, Takashima A, Yamada M, Naiki H. 2002. Nordihydroguaiaretic acid potently breaks down pre-formed Alzheimer's beta-amyloid fibrils in vitro. J Neurochem 81:434-440.
30. Ono K, Yoshiike Y, Takashima A, Hasegawa K, Naiki H, Yamada M. 2003. Potent anti-amyloidogenic and fibril-destabilizing effects of polyphenols in vitro: implications for the prevention and therapeutics of Alzheimer's disease. J Neurochem 87:172-181.
31. Ono K, Hasegawa K, Naiki H, Yamada M. 2006. Anti-Parkinsonian agents have anti-amyloidogenic activity for Alzheimer's beta-amyloid fibrils in vitro. Neurochem Int 48:275-285.
32. Ono K, Yamada M. 2006. Antioxidant compounds have potent anti-fibrillogenic and fibril-destabilizing effects for alpha-synuclein fibrils in vitro. J Neurochem 97:105-115.
33. Ono K, Yamada M. 2007. Vitamin A potendy destabilizes preformed α-synuclein fibrils in vitro: implications for Lewy body diseases. Neurobiol Dis 25:446-454.
34. Ostrerova-Golts N, Petracelli L, Hardy J, Lee JM, Farer M, Wolozin B. 2000. The A53T alpha-synuclein mutation increases iron-dependent aggregation and toxicity. J Neurosci 20:6048-6054.
35. Palhagen S, Heinonen EH, Hagglund J, Kaugesaar T, Kontants H, MakiIkola O, Palm R, Turunen J. 1998. Selegiline delays the onset of disability in de novo Parkinsonian patients. Swedish Parkinson Study Group. Neurology 51:520-525.
36. Palhagen S, Heinonen E, Hagglund J, Kaugesaar T, Maki-Ikola O, Palm R,Swedish Parkinson Study Group. 2006. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 66:1200-1206.
37. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, Nussbaum RL. 1997. Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science 276:2045-2047.
38. Prasad KN, Cole WC, Kumar B. 1999. Multiple antioxidants in the prevention and treatment of Parkinson's disease. J Am Coll Nutr 18:413-423.
39. Sharma SK, Carlson EC, Ebadi M. 2003. Neuroprotective actions of Selegiline in inhibiting 1-methyl, 4-phenyl, pyridinium ion (MPP+)-induced apoptosis in SK-N-SH neurons. J Neurocytol 32:329-343.
40. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K. 2003. alpha-Synuclein locus triplication causes Parkinson's disease. Science 302:841.
41. Spencer JP, Jenner A, Butler J, Aruoma OI, Dexter DT, Jenner P, Halliwell B. 1996. Evaluation of the pro-oxidant and antioxidant actions of L-dopa and dopamine in vitro: implications for Parkinson's disease. Free Radic Res 24:95-105.
42. Trojanowski JQ, Lee VM. 2003. Parkinson's disease and related alpha-synucleinopathies are brain amyloidoses. Ann NY Acad Sci 991:107-110.
43. Uversky VN, Lee HJ, Li J, Fink AL, Lee SJ. 2001a. Stabilization of partially folded conformation during alpha-synuclein oligomerization in both purified and cytosolic preparations. J Biol Chem 276:43495-43498.
44. Uversky VN, Li J, Fink AL. 2001b. Evidence for a partially folded intermediate in alpha-synuclein fibril formation. J Biol Chem 276:10737-10744.
45. Volles MJ, Lansbury PT Jr. 2003. Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry 42:7871-7878.
46. Wood SJ, Wypych J, Steavenson S, Louis JC, Citron M, Biere AL. 1999. alpha-synuclein fibrillogenesis is nucleation-dependent. Implications for the pathogenesis of Parkinson's disease. J Biol Chem 274: 19509-19512.
47. Wu RM, Chiueh CC, Pert A, Murphy DL. 1993. Apparent antioxidant effect of l-deprenyl on hydroxyl radical formation and nigral injury elicited by MPP+ in vivo. Eur J Pharmacol 243:241-247.
48. Yazawa I, Giasson BI, Sasaki R, Zhang B, Joyce S, Uryu K, Trojanowski JQ, Lee VM. 2005. Mouse model of multiple system atrophy alpha-synuclein expression in oligodendrocytes causes glial and neuronal degeneration. Neuron 45:847-859.
49. Yen GC, Hsieh CL. 1997. Antioxidant effects of dopamine and related compounds. Biosci Biotechnol Biochem 61:1646-1649.
50. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, de Yebenes JG. 2004. The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia. Ann Neurol 55:164-173.
51. Zhang Y, Dawson VL, Dawson TM. 2000. Oxidative stress and genetics in the pathogenesis of Parkinson's disease. Neurobiol Dis 7:240-250.